Japan’s MHLW approves GSK’s Blenrep combos for multiple myeloma
The decision is grounded in the positive outcomes from the Phase III trials: DREAMM-7 and DREAMM-8.
Approvals
FDA approves Incyte’s retifanlimab combo for SCAC treatment
EC approves BMS’ perioperative Opdivo and chemo for NSCLC
FDA approves Amneal’s DHE migraine/cluster headache autoinjector
FDA awards cancer drug approvals to AbbVie and MSD
FDA awards BioCryst’s Orladeyo NDA for paediatric HAE
Kaerus gains FDA designations for Fragile X syndrome treatment
Japan’s MHLW approves Sarepta’s gene therapy for DMD
